ChemoCentryx to Present at Two Upcoming Investor Conferences
ChemoCentryx, Inc. (Nasdaq: CCXI) announced that CEO Thomas J. Schall, Ph.D. will present at two investor conferences. The 40th Annual J.P. Morgan Healthcare Conference is scheduled for January 12 at 4:30 p.m. ET, while the H.C. Wainwright Virtual BioConnect Conference will have an on-demand presentation available starting January 10 at 7:00 a.m. ET. Both presentations can be accessed via the company's website, with replays available for two weeks after.
ChemoCentryx specializes in developing treatments for inflammatory and autoimmune diseases and cancer.
- None.
- None.
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences:
- 40th Annual J.P. Morgan Healthcare Conference
Wednesday, January 12 at 4:30 p.m. Eastern Time
- H.C. Wainwright Virtual BioConnect Conference
On-demand presentation available beginning Monday, January 10 at 7:00 a.m. Eastern Time
A live audio webcast of the J.P. Morgan presentation, as well as the on-demand H.C. Wainwright presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. Replays of both presentations will be available on the Company's website for two weeks following the respective presentation dates.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS™ (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com
Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com
Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com
FAQ
When will ChemoCentryx present at the J.P. Morgan Healthcare Conference?
What is the H.C. Wainwright Virtual BioConnect Conference schedule?
How can I access ChemoCentryx's conference presentations?
What is ChemoCentryx focused on developing?
What is TAVNEOS and its significance?
